Garetosmab Biosimilar Monoclonal Antibody (Activin A) for Research
Pre-Made Garetosmab biosimilar, Whole mAb, Anti-INHBA/ACT Antibody: Anti-EDF/FRP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Garetosmab is a VelocImmune-derived fully-human monoclonal antibody that binds and neutralizes Activin A, which is involved in the development of heterotopic bone in people with FOP. Garetosmab is currently being studied in adults with FOP.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-234-1mg | 1mg | 618 |
Size: 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Garetosmab biosimilar, Whole mAb, Anti-INHBA/ACT Antibody: Anti-EDF/FRP therapeutic antibody |
| INN Name | Garetosmab |
| Target | ACT |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Regeneron Pharmaceuticals |
| Conditions Approved | na |
| Conditions Active | Fibrodysplasia ossificans progressiva;Osteroporosis |
| Conditions Discontinued | Musculoskeletal disorders |
| Development Tech | na |
About target - INHBA
1. Protein Inhibin beta A chain
2. Gene INHBA
3. Organism Homo sapiens (Human)
Function
Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland. Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition. Inhibins appear to oppose the functions of activins.

